What is the current market price reference for Mirdametinib per box?

As of2025 July , Midametinib (Midametinib, trade name: GOMEKLI) has not been approved for marketing in China by the National Medical Products Administration (NMPA), so it cannot be purchased and used through formal channels in China. This drug is mainly used to treat adult and pediatric patients with neurofibromatosis 1 type (NF1) and symptomatic plexiform schwannoma (PN). Currently, if patients want to use the drug, they may need to participate in international clinical trials or purchase drugs overseas. However, these routes involve certain legal and regulatory risks and may result in high costs.

In the international market, the price of Midametinib varies depending on the region and purchasing channel. For example, in the United States, the price of midametinib can range from a few thousand dollars to tens of thousands of dollars, depending on the dose purchased and the supplier. Prices may also vary in the EU and other regions. It should be noted that these prices usually apply to purchases through formal channels, and patients should be cautious when choosing purchase channels to ensure the quality and legality of the drugs.

In addition, midametinib has not yet been included in China's national medical insurance directory and therefore cannot be reimbursed through the Chinese medical insurance system. This means that patients need to bear all costs when using the drug in China, which may impose a greater burden on patients with poor financial conditions. Currently, there are no specific drugs for NF1symptomatic plexiform schwannoma in China. The introduction of midametinib may provide new treatment options for patients.

In general, midametinib has not yet been approved for marketing in China, and patients in the country cannot purchase and use the drug through formal channels. If you are considering using this medication, it is recommended that you discuss it in detail with a medical professional to assess its indications, potential risks and possible access. At the same time, pay attention to the latest developments from China’s drug regulatory authorities to obtain the latest information on the drug’s launch in China.

Reference materials:https://www.drugs.com/